SeekingAlpha  May 3  Comment 
newratings.com  Mar 28  Comment 
JERUSALEM (dpa-AFX) - Allergan plc (AGN) and Paratek Pharmaceuticals Inc. (PRTK) announced positive results from two phase III trials of Sarecycline for the treatment of moderate to severe acne. The trials, SC1401 and SC1402, have met their 12...
FierceBiotech  Mar 27  Comment 
Liver cancer miss adds to litany of trial failures for ArQule's tivantinib phil Mon, 03/27/2017 - 09:04
GenEng News  Mar 27  Comment 
ArQule’s lead candidate, the c-Met receptor tyrosine kinase inhibitor tivantinib, missed its primary progression-free survival (PFS) endpoint in a second Phase III study reported in as many months. The placebo-controlled JET-HCC study, carried...
SeekingAlpha  Mar 7  Comment 



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki